LogicBio Therapeutics (OTCMKTS:LOGC) Releases Earnings Results, Misses Estimates By $0.10 EPS

LogicBio Therapeutics (OTCMKTS:LOGC) announced its quarterly earnings results on Thursday. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.10), Zacks reports. The firm had revenue of $33.60 million during the quarter, compared to the consensus estimate of $33.60 million.

LogicBio Therapeutics Price Performance

LogicBio Therapeutics stock opened at $11.17 on Friday. The stock has a market capitalization of $510.80 million, a price-to-earnings ratio of -10.25 and a beta of 2.02. LogicBio Therapeutics has a 52-week low of $7.05 and a 52-week high of $11.21. The company has a debt-to-equity ratio of 0.28, a quick ratio of 1.15 and a current ratio of 1.67. The stock’s 50 day moving average price is $9.43 and its two-hundred day moving average price is $8.69.

Institutional Trading of LogicBio Therapeutics

An institutional investor recently raised its position in LogicBio Therapeutics stock. Goldman Sachs Group Inc. raised its holdings in shares of LogicBio Therapeutics, Inc. (OTCMKTS:LOGC) by 284.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 526,673 shares of the company’s stock after purchasing an additional 389,843 shares during the quarter. Goldman Sachs Group Inc. owned 2.00% of LogicBio Therapeutics worth $3,676,000 as of its most recent SEC filing. 46.05% of the stock is owned by hedge funds and other institutional investors.

LogicBio Therapeutics Company Profile

LogicBio Therapeutics, Inc, a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia.